STOCK TITAN

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has announced an upcoming poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will take place in Houston, Texas, from November 6-10, 2024.

The company plans to present preclinical data from its tumor-activated SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR) format. The poster, titled "Tumor-activated immune cell engagers designed to drive synthetic immunity against cancer demonstrated protease-dependent activation and robust anti-tumor activity in preclinical models," will be presented on Saturday, Nov. 9, 2024. The presentation will be available for viewing during the lunch and poster viewing session from 12:15 – 1:45 p.m. CST and during the poster reception from 7:10 – 8:40 p.m. CST at the George R. Brown Convention Center.

Xilio Therapeutics, Inc. (Nasdaq: XLO), un'azienda biotecnologica in fase clinica focalizzata su terapie immuno-oncologiche attivate dai tumori, ha annunciato una prossima presentazione di poster durante il 39° Meeting Annuale della Society for Immunotherapy of Cancer (SITC). L'evento si svolgerà a Houston, Texas, dal 6 al 10 novembre 2024.

L'azienda prevede di presentare dati preclinici dal suo formato di SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR) attivato dai tumori. Il poster, intitolato "Engager delle cellule immunitarie attivato dai tumori progettati per promuovere l'immunità sintetica contro il cancro ha dimostrato un'attivazione dipendente dalle proteasi e una robusta attività anti-tumorale in modelli preclinici", sarà presentato sabato 9 novembre 2024. La presentazione sarà disponibile per la visione durante la sessione di pranzo e visione dei poster dalle 12:15 alle 13:45 CST e durante la reception dei poster dalle 19:10 alle 20:40 CST al George R. Brown Convention Center.

Xilio Therapeutics, Inc. (Nasdaq: XLO), una compañía biotecnológica en fase clínica enfocada en terapias de inmuno-oncología activadas por tumores, ha anunciado una próxima presentación de poster en el 39º Congreso Anual de la Sociedad para la Inmunoterapia del Cáncer (SITC). El evento tendrá lugar en Houston, Texas, del 6 al 10 de noviembre de 2024.

La empresa planea presentar datos preclínicos de su formato de SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR) activado por tumores. El poster, titulado "Engagers de células inmunitarias activados por tumores diseñados para impulsar la inmunidad sintética contra el cáncer demostraron activación dependiente de proteasas y robusta actividad anti-tumoral en modelos preclínicos", será presentado el sábado 9 de noviembre de 2024. La presentación estará disponible para visualización durante la sesión de almuerzo y visualización de posters de 12:15 a 13:45 CST y durante la recepción de posters de 19:10 a 20:40 CST en el George R. Brown Convention Center.

Xilio Therapeutics, Inc. (Nasdaq: XLO)는 종양 활성화 면역 종양학 치료에 중점을 둔 임상 단계의 생명공학 회사로, 제39회 암 면역치료 학회(SITC)에서 포스터 발표를 예정하고 있음을 발표했습니다. 이 행사는 2024년 11월 6일부터 10일까지 텍사스주 휴스턴에서 개최됩니다.

회사는 종양 활성화 SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR) 형태의 전임상 데이터를 발표할 예정입니다. "종양 활성화 면역 세포 약물은 합성 면역을 유도하도록 설계되어 단백질 분해 효소 의존적인 활성화 및 전임상 모델에서 강력한 항종양 활성을 입증했다"는 제목의 포스터는 2024년 11월 9일 토요일에 발표될 것입니다. 발표는 CST 기준으로 오후 12:15부터 1:45까지의 점심 및 포스터 관람 세션과 오후 7:10부터 8:40까지의 포스터 리셉션 동안 관람할 수 있습니다. 발표 장소는 조지 R. 브라운 컨벤션 센터입니다.

Xilio Therapeutics, Inc. (Nasdaq: XLO), une société biopharmaceutique en phase clinique axée sur les thérapies immuno-oncologiques activées par les tumeurs, a annoncé une prochaine présentation de poster lors de la 39ème Réunion Annuelle de la Société pour l'Immunothérapie du Cancer (SITC). L'événement se déroulera à Houston, Texas, du 6 au 10 novembre 2024.

La société prévoit de présenter des données précliniques de son format de SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR) activé par les tumeurs. Le poster, intitulé "Engagers de cellules immunitaires activés par des tumeurs conçus pour stimuler une immunité synthétique contre le cancer ont démontré une activation dépendante des protéases et une activité anti-tumorale robuste dans des modèles précliniques", sera présenté le samedi 9 novembre 2024. La présentation sera disponible pour consultation pendant la session déjeuner et de visualisation des posters de 12h15 à 13h45 CST et lors de la réception des posters de 19h10 à 20h40 CST au George R. Brown Convention Center.

Xilio Therapeutics, Inc. (Nasdaq: XLO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf tumoraktivierte Immunonkotherapien fokussiert, hat eine bevorstehende Posterpräsentation bei der 39. Jahrestagung der Society for Immunotherapy of Cancer (SITC) angekündigt. Die Veranstaltung findet vom 6. bis 10. November 2024 in Houston, Texas, statt.

Das Unternehmen plant, vorklinische Daten aus seinem tumoraktivierten SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR)-Format zu präsentieren. Das Poster mit dem Titel "Tumoraktivierte Immunzellengager, die entwickelt wurden, um synthetische Immunität gegen Krebs zu fördern, zeigten proteaseabhängige Aktivierung und robuste anti-tumorale Aktivität in vorklinischen Modellen" wird am Samstag, den 9. November 2024, präsentiert. Die Präsentation ist während der Mittags- und Posteransichtssitzung von 12:15 bis 13:45 Uhr CST und während des Posterempfangs von 19:10 bis 20:40 Uhr CST im George R. Brown Convention Center verfügbar.

Positive
  • Xilio Therapeutics will present preclinical data on its tumor-activated SEECR format at a major cancer research conference
  • The preclinical data demonstrates protease-dependent activation and robust anti-tumor activity
Negative
  • None.

WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, Texas, from November 6-10, 2024. The company plans to present preclinical data from its tumor-activated SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR) format.

Poster presentation details:

  • Title: Tumor-activated immune cell engagers designed to drive synthetic immunity against cancer demonstrated protease-dependent activation and robust anti-tumor activity in preclinical models
  • Abstract Number: 1296
  • Presentation Date: Saturday, Nov. 9, 2024
  • Time: Lunch and Poster Viewing: 12:15 – 1:45 p.m. CST; Poster reception: 7:10 – 8:40 p.m. CST
  • Location: George R. Brown Convention Center

About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans to present preclinical data related to Xilio’s tumor-activated cell engager programs; and Xilio’s strategy, goals, business plans and focus. The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, general market conditions; risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such preclinical studies or clinical trials; the delay of any current or planned preclinical studies or clinical trials or the development of Xilio’s current or future product candidates; Xilio’s ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates; Xilio’s advancement of multiple early-stage immune cell engager programs, including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers; interim or preliminary preclinical or clinical data or results, which may not be replicated in or predictive of future preclinical or clinical data or results; Xilio’s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; results from preclinical studies or clinical trials for Xilio’s product candidates, which may not support further development of such product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of current or future clinical trials; Xilio’s ability to obtain, maintain and enforce patent and other intellectual property protection for current or future product candidates; Xilio’s ability to obtain and maintain sufficient cash resources to fund its operations; the impact of international trade policies on Xilio’s business, including U.S. and China trade policies; Xilio’s ability to maintain its clinical trial collaboration with Roche to develop XTX101 in combination with atezolizumab; and Xilio’s ability to maintain its license agreement with Gilead to develop and commercialize XTX301. These and other risks and uncertainties are described in greater detail in the sections entitled “Risk Factor Summary” and “Risk Factors” in Xilio’s filings with the U.S. Securities and Exchange Commission (SEC), including Xilio’s most recent Quarterly Report on Form 10-Q and any other filings that Xilio has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Xilio’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio explicitly disclaims any obligation to update any forward-looking statements.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Investor and Media Contact: 
Scott Young
Vice President, Investor Relations and Corporate Communications
investors@xiliotx.com


FAQ

When and where will Xilio Therapeutics (XLO) present its poster at the SITC 39th Annual Meeting?

Xilio Therapeutics will present its poster on Saturday, November 9, 2024, at the George R. Brown Convention Center in Houston, Texas. The poster will be available for viewing during the lunch and poster session from 12:15 – 1:45 p.m. CST and during the poster reception from 7:10 – 8:40 p.m. CST.

What type of data will Xilio Therapeutics (XLO) present at the SITC 39th Annual Meeting?

Xilio Therapeutics will present preclinical data from its tumor-activated SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR) format, demonstrating protease-dependent activation and robust anti-tumor activity in preclinical models.

What is the title of Xilio Therapeutics' (XLO) poster presentation at the SITC 39th Annual Meeting?

The title of Xilio Therapeutics' poster presentation is "Tumor-activated immune cell engagers designed to drive synthetic immunity against cancer demonstrated protease-dependent activation and robust anti-tumor activity in preclinical models."

Xilio Therapeutics, Inc.

NASDAQ:XLO

XLO Rankings

XLO Latest News

XLO Stock Data

41.81M
25.97M
40.92%
33.5%
0.9%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WALTHAM